HedgeRoll - Value Investing and After Tax Returns
  • HedgeRoll
  • Contact
  • Research

hedgeroll

In Search of After-Tax returns

biotech as buffett's wonderful business

4/28/2014

1 Comment

 



Most people would say Warren Buffett, the famously tech-adverse investor who seeks "Wonderful Businesses", would never touch the biotechnology sector. However I believe this is simply a function of his  circle of competence principal.  Simply, if he doesn't fully understand a business, he won't allocate it his capital.

Do some  investor's circle of competence include biotech? Of course, but does the biotech sector contain "Wonderful Businesses"? Let's find out.
Time is the friend of the wonderful business, the enemy of the mediocre.
-Warren Buffett, 1989 Chairman's Letter
Picture
So what is a Wonderful Business? Investopedia has a nicesummary of Buffett's wonderful business criteria:

Buffett's criteria for "wonderful businesses" include, among others, the following:
  1. They have a good return on capital without a lot of debt.
  2. They are understandable.
  3. They see their profits in cash flow.
  4. They have strong franchises and, therefore, freedom to price.
  5. They don't take a genius to run.
  6. Their earnings are predictable.
  7. The management is owner-oriented.

For the purposes of this post, I am going to focus on the factors we can easily quantify, specifically items one and three. Return On Invested Capital, item one, is certainly the most important. It's also worth noting that this criteria works. 
"Leaving the question of price aside, the best business to own is one that over an 
extended period can employ large amounts of incremental capital at very high rates 
of return.  The worst business to own is one that must, or will, do the opposite - that
is, consistently employ ever-greater amounts of capital at very low rates of return."     
-Warren Buffett, 1992 Chairman's Letter
There are many "cheap" companies, but not many that earn high returns on capital. Let's look at Berkshire Hathaway's publicly traded holdings to see what Buffett considers an acceptable ROIC.
Picture
For those who completely dismiss The Oracle's interest in biotech, I will point to Berkshire Hathaway's quarterly 13F filing. As of December 31, 2013 Bershire owned shares in Sanofi Aventis and Johnson & Johnson.  Although these are "pharma" and not "biotech", the truth is that the distinction between the two sectors has been getting blurrier every year.  Biotech is simply next-generation pharma. Case in point, J&J is the world's fifth largest biologics company, and Sanofi's Tuberculin for diagnosis of  tuberculosis is a Purified Protein Derivative. 

Let's check out the ROIC's  of Berkshire Hathaway's healthcare companies. (Yes, I know DaVita is not Buffett's position, but rather Ted Weschler's)  Also, they recently sold out of GSK, but it's worth noting for our purposes.
Picture
So we've established that Berkshire Hathaway, and by extension Buffett, has invested (to a limited extent) in companies that sell biotechnology products.  But what about the criteria outlined above? What about a pure play biotech company?

Gilead Sciences is the second largest component of the NASDAQ Biotechnology Index at 8.4%. This maker of Hepatitis and HIV antiviral drugs was founded in 1987 and then went public in January 1992. 

Gilead has followed the path of many growing companies, operating at a loss for the first several years before finding success. It wasn't until the second quarter of 2002 that Gilead earned a profit, and since then it has earned an excellent average ROIC of 26.9% over the past five years, nearly as much as Buffett's fourth largest holding IBM.

Below I've shown regular ROIC, and Cash Return on Capital Invested, to smooth out some accounting charges that do not impact cash.
Picture
What about criteria number three, profits as cash flow? Turns out Gilead is pretty good there too, with the same exceptions of some accounting write downs, Earnings and Cash Flow from Operations have tracked each other very closely.
Picture
So we've established that biotechnology can, quantitatively, meet the definition of a "Wonderful Business". 

Interesting side notes: 
  • Michael L Riordan, Gilead Founder  attempted to recruit Warren Buffett as a board member in 1988. Buffett quipped "Sorry, but I would bring nothing to this enterprise except my name".
  • To further illustrate the blurring lines between pharma and biotech, Gilead's antivirals are small molecule drugs, which are typically associated with pharmaceutical companies.
  • Since Gilead started earning a profit in 2002, the stock has gone up.  See below. Like I said earlier, this stuff works.
Picture
It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.
-Warren Buffett, 1989 Chairman's Letter
Email Marketing You Can Trust
All data from ycharts.com

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
1 Comment
Forex Trading Tips in India link
8/3/2014 09:22:03 pm

I am always in search of such articles and posts which provide genuine information and I must say my search ends on this post. Thanks for the share mate.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Picture
    This is the personal blog of Emory Redd.

    This blog is not investment advice. This is not a solicitation to invest. Don't take candy from strangers.
    Follow @Emory_R
    View my profile on LinkedIn
    BEST OF HEDGEROLL
    ACHILLION AND RA CAPITAL: MY FAVORITE TRADE

    SALIX INVESTORS LOOKING FOR A BUYOUT SHOULD BE CAUTIOUS; MORE ACCOUNTING PROBLEMS AHEAD

    BIOTECH AS BUFFETT'S WONDERFUL BUSINESS
    Get Email Updates

    Categories

    All
    13D
    13F
    13G
    Abingworth
    Accounting
    Accounting Fraud
    Achillion ACHN
    Activist
    AGN
    Aig
    Alphasimplex Group
    American Express
    Andrew Lo
    ANTH
    Anthera Pharmaceuticals
    Anthony Scaramucci
    Arbitrage
    ARC-520
    Argonaut Capital Management
    Arrowhead Research
    Artemis
    ARWR
    ASH 2014
    Avenue Capital
    AXP
    Baker Bros. Advisors
    Baker Brothers
    Barton Biggs
    Baupost Group
    BB Biotech
    Bear Stearns
    Beneish M-Score
    BenjaminJGarber.com
    Bershire Hathaway
    Bill Gross
    Biotech Hedge Fund
    Biotechnology
    Biotech Trader Handbook
    Biotech Valuation
    Black Swan
    BMY
    Bob Treue
    Bonds
    Books
    Broadfin Capital
    Bruce Greenwald
    Bubble
    Capital Returns Management
    Carl Icahn
    Carlos Slim
    Carnegie Mellon
    Celgene (CELG)
    Channel-stuffing
    Charlie Munger
    China
    Chris Levett
    Circle-of-competence
    Clive Capital
    Coca-Cola Company
    Coke KO
    Columbia Business School
    Commodities
    Contrarian Trades
    Credit
    Credit Bubble
    Cta
    Currency
    Daniel Gold
    Data Mining
    David Einhorn
    David Gerstenhaber
    David Harding
    David Tepper
    Davita Inc
    D.E. Shaw
    Deutsche Bank
    Donald Trump
    Dunn & Bradstreet DNB
    Dva
    Earnings Manipulation
    Eric Sprott
    Fabozzi-books
    Fed Day
    Federated Investors
    Fees
    Fig
    Fixed Income
    Form 4
    Fortress Investment Group Llc
    Fund Of Funds
    Gartmore
    GILD
    Gilead
    Glaxosmithkline
    Global Macro
    Gold
    Goldman Sachs
    Gotham Capital
    GSK
    HBV
    HCV
    Hedge Fund Start-up
    Hepatitis B
    Hepatitis C
    HIV
    Humor
    IBM
    IgA Nephropathy
    Inflation
    Insurance Companies
    Intellectual Property
    International Business Machines
    Izzy Englander
    Jeffrey Ubben
    JNJ
    Joel Greenblatt
    John Paulson
    Johnson & Johnson
    John W Henry
    Julian Robertson
    Kkr
    KO
    Leon Cooperman
    Loeb
    Long Term Capital Management
    Lupus
    M&A
    Man Group
    Marc Lasry
    Mellon
    Michael Bloomberg
    Michael Burry
    Michael Lewis
    Michael L Roirdan
    Michael Novogratz
    Michael Steinhardt
    Millennium Partners
    Moody's MCO
    Mr. T
    MRX
    Municipal Bonds
    Music
    Nassim Taleb
    Obama
    Occupy Wall Street
    Oil
    Omega Advisors
    Oncology
    Orbimed Advisors
    Orphan Disease
    Palo Alto Investors
    Paul Tudor Jones Iii
    Perceptive Advisors
    Pershing Square
    PG
    Pharmacyclics (PCYC)
    Phil Falcone
    Point State Capital
    Private Equity
    Procter & Gamble
    Quantitative Easing
    Quants
    QVT Financial
    RA Capital
    Redmile Group
    Return On Invested Capital
    Rob Bobman
    Robert Shiller
    Rob Goldstein
    ROIC
    Salix Pharmaceuticals SLXP
    Sanofi-Aventis
    Sebastian Mallaby
    Sec
    Seeding
    Seth Klarman
    Shorts
    Short Selling
    Short Selling Books
    Silver
    Skybridge
    SLXP
    SNY
    Stanley Druckenmiller
    Statistical Arbitrage
    St Joe Company
    Sub-Prime
    Ted Weschler
    The Barnegat Fund
    Thomas Mellon
    Traxis Partners
    Twitter
    Twitter Hedge Fund
    Valeant
    ValueAct
    Value Investing
    Vanderbilt
    VHCP Management
    Victor Niederhoffer
    VRX
    Warren Buffett
    Warren Buffett Letters
    Wells Fargo
    Wfc
    When Stocks Crash Nicely
    William Ackman
    Winton Capital Management
    Wonderful Business
    Yale University

    Archives

    December 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    December 2014
    November 2014
    October 2014
    August 2014
    April 2014
    August 2013
    October 2012
    September 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • HedgeRoll
  • Contact
  • Research